Facebook
Twitter
LinkedIn
ForwardTransplant & Cell Therapies Annual Symposium: The Changing COVID Landscape
Description
This year’s program will examine the impact of COVID-19 on stem cell transplant and cellular therapies as well as important topics related to short- and long-term survivorship.
Target Audience
This activity is intended for hematologist/oncologists, nurses, PAs, pharmacists, case managers, and insurance payors involved in the care of transplant and CAR-T patients.
Learning Objectives
Upon completion of the activity, participants will be able to:
- Discuss latest therapies in transplant research and clinical practice and understand the impact of COVID19 on stem cell transplant donors and recipients
- Demonstrate of the use of different methods of transplantation and CAR-T and their practicality, especially during the COVID19 pandemic
- Review impact of COVID19 on post-transplant care and understand other non-infectious concerns that may present during short-term and long-term recovery from treatment
- Review post-transplant survivorship and long-term follow-up requirements and understand how post-transplant survivorship should be approved by referring providers and oncologists
- Identify common and uncommon post-treatment toxicities and differentiate between various common, chronic, and advanced infections post-treatment
- Review medical policy and how transplants are managed at Blue Cross Blue Shield MA including complex case management and how working together can improve the patient experience.
Additional Information
Dana-Farber Cancer Institute and Mass General Brigham
Corey Cutler, MD, MPH - Course Director
Medical Director, Division of Transplant and Cellular Therapies,
Dana-Farber/Brigham and Women’s Cancer Center
Amy Emmert, MScPH
Vice President, Dana-Farber/Brigham and Women’s Cancer Center
Sarah Hammond, MD
Director of Infectious Disease for Hematology Oncology,
Massachusetts General Hospital
Caron Jacobson, MD
MMSc, Medical Director, IEC Program,
Dana-Farber/Brigham and Women’s Cancer Center
Leslie Lehmann, MD
Clinical Director, Stem Cell Transplant,
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Clifton Mo, MD
Director of Autologous Transplant for Multiple Myeloma,
Dana-Farber/Brigham and Women’s Cancer Center
Desiree Otenti, NP
Senior Director, Blue Cross Blue Shield Massachusetts
Rizwan Romee, MD
Director, Haploidentical Donor Transplantation Program
Dana-Farber/Brigham and Women’s Cancer Center
Accreditation
Mass General Brigham is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Mass General Brigham designates this live activity for a maximum of 4 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing CE
Dana-Farber Cancer Institute is an approved provider of continuing nursing education by the American Nurses Association Massachusetts, an accredited approver by the American Nurses’ Credentialing Center’s Commission on Accreditation. Nurses should claim only the credit commensurate with the extent of their participation in the activity. A maximum of 3.75 Contact Hours will be awarded upon completion of an evaluation.
Available Credit
- 4.00 AMA PRA Category 1 Credit™
- 3.75 Nursing Contact Hours
- 4.00 Participation